1. Zhu N, et al. A novel coronavirus from patients with pneumonia in China. N. Engl. J. Med. 2019; 382 (8), 727–733.
2. Jiang S, Hillyer C, Du L. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. Trends Immunol. 2020; 41 (5), 355–359.
3. Siddiqi HK, Mehra,MR. COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal. J. Hear. Lung Transplant. 2020; 39 (5), 405–407.
4. Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. JAMA – J. Am. Med. Assoc. 2020; 323 (13), 1239–1242.
5. Van Doremalen N, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N. Engl. J. Med. 2020; 382 (24), 1564–1567.
6. CCSS. COVID-19 CCSS | Estadísticas. (2020). Disponible en: https://www.ccss.sa.cr/web/coronavirus/estadistica.
7. Petherick A. Developing antibody tests for SARS-CoV-2. Lancet. 2020; 395 (10230), 1101–1102.
8. Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection. Ann. Intern. Med. 2020; 173 (5), 362-367.
9. Ivashkiv LB, Donlin,LT. Regulation of type i interferon responses. Nat. Rev. Immunol. 2014; 14 (1), 36–49.
10. Thevarajan Irani, LS. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat. Med. 2020; 26 (4), 450–452.
11. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia. Emerg. Microbes Infect. 2020; 9(1), 727–732.
12. Tay MZ, Poh CM, Rénia L, MacAry, PA Ng, FP. The trinity of COVID-19: immunity, inflammation and intervention. Nat. Rev. Immunol. 2020; 20(6), 363–374.
13. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 2019; 17(3), 181–192.
14. Sethuraman N, Jeremiah SS, Ryo, A. Interpreting Diagnostic Tests for SARS-CoV-2. Jama. 2019; 323 (22), 2249-2251.
15. Burbelo PD, et al. Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019. J. Infect. Dis. 2020; 222(2), 206–213.
16. Okba N. et al. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. Emerg. Infect. Dis. 2020; 26(7), 1478–1488.
17. Krammer F, Simon V. Serology assays to manage COVID-19. Science. 2020(6495); 368, 1060–1061 (2020).
18. Wu F, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered 2 patient cohort and their implications. medRxiv https://doi.org/10.1101/2020.03.30.20047365 (2020).
19. Yan R, Zhang Y, Guo, Y, Xia L, Zhou Q. Structural basis for the recognition of the 2019-nCoV by human ACE2. Science 2020; 2762, 1–10.
20. Vabret N, et al. Immunology of COVID-19: current state of the science. Immunity 2020. doi:10.1016/j.immuni.2020.05.002
21. Brochot E, et al. Anti-Spike anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 hospitalized patients and asymptomatic carriers. Medrxiv. 2020; 1–25. doi:10.1101/2020.05.12.20098236
22. Wölfel R, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020; 581(7809), 465–469.
23. To KK, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect. Dis. 2020; 20(5), 565–574.
24. Wang , et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA – J. Am. Med. Assoc. 2020; 323(18), 1843–1844.
25. Zhao J, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin. Infect. Dis. 2020; 71(16), 1–22. doi:10.1093/cid/ciaa344
26. Whitman JD, et al. Test performance evaluation of SARS-CoV-2 serological assays. medRxiv Prepr. Serv. Heal. Sci. 2020; 29, 30.
27. FDA. EUA Authorized Serology Test Performance | FDA. (2020). Disponible en: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance. (Accessed: 9th September 2020)
28. FIND. FIND evaluation update: SARS-CoV-2 immunoassays – FIND. (2020). Disponible en: https://www.finddx.org/covid-19/sarscov2-eval-immuno/. (Accessed: 9th September 2020)
29. Nie J, et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg. Microbes Infect. 2020; 9(1), 680–686.
30. Muruato AE, et al. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat. Commun. 2020; 11(1), 1-6.
31. GeurtsvanKessel CH, et al. An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. Nat. Commun. 2020; 11(5), 1-5.
32. Guzman MG, et al. Dengue : a continuing global threat. Nat. Publ. Gr. 2010; 8(12), S7–S16.
33. Weaver SC, Lecuit M. Chikungunya virus and the global spread of a mosquito-borne disease. New England Journal of Medicine. 2015; 372(13), 1231–1239.
34. Long Q.-X, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 2020; 26(6), 845-848. doi:10.1038/s41591-020-0897-1
35. Lou B, et al. Serology characteristics of SARS-CoV-2 infection since the exposure and post symptoms onset. medRxiv 2020.03.23.20041707 (2020). doi:10.1101/2020.03.23.20041707
36. Wu F, et al. Neutralizing Antibody Responses to SARS-CoV-2 in a COVID-19 Recovered Patient Cohort and Their Implications. SSRN Electron. J. 2020.03.30.20047365 (2020). doi:10.1101/2020.03.30.20047365
37. Garcia-Basteiro AL, et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nature Communications. 2020;11(1), 1-9.
38. Padoan A, et al. IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study. Clin. Chim. Acta. 2020; 507(1), 164–166.
39. Yu H, et al. Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients. Eur. Respir. J. 2001526 (2020). doi:10.1183/13993003.01526-2020
40. Hu Q, et al. The Production and Clinical Implications of SARS-CoV-2 Antibodies. SSRN Electron. J. 2020.04.20.20065953 (2020). doi:10.1101/2020.04.20.20065953
41. Hanson KE, et al. Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Serologic Testing. www.idsociety.org/COVID19guidelines/serology. (2020). Disponble en: www.idsociety.org/COVID19guidelines/serology.
42. Tan W, et al. Viral Kinetics and Antibody Responses in Patients with COVID-19. medRxiv 2020.03.24.20042382 (2020). doi:10.1101/2020.03.24.20042382
43. Huang J, et al. Long period dynamics of viral load and antibodies for SARS-CoV-2 infection: an observational cohort study. medRxiv (Cold Spring Harbor Laboratory Press, 2020). doi:10.1101/2020.04.22.20071258
44. Altmann DM, Douek DC, Boyton RJ. What policy makers need to know about COVID-19 protective immunity. The Lancet. 2020; 395(10236), 1527–1529.
45. Wang X, et al. Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients. Clin. Infect. Dis. 2020 71(10), 2688-2694. doi:10.1093/cid/ciaa721
46. Iwasaki A, Yang, Y. The potential danger of suboptimal antibody responses in COVID-19. Nat. Rev. Immunol. 2020; 20(6), 339-341. doi:10.1038/s41577-020-0321-6
47. Wu J, et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19 Correspondence. medRxiv 2020.07.21.20159178 (2020). doi:10.1101/2020.07.21.20159178
48. To KK-W, et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clin. Infect. Dis. 2020. doi:10.1093/cid/ciaa1275
49. Ismail, A. ANNALS EXPRESS: Serological tests for Covid-19 antibodies: limitations must be recognised. Ann. Clin. Biochem. Int. J. Lab. Med. 2020;57(4),274-276. 000456322092705. 2020. doi:10.1177/0004563220927053
50. Salje H, et al. Estimating the burden of SARS-CoV-2 in France. Science. 2020; 369(6500), 208–211.
51. Guo L, et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin. Infect. Dis. 2020; 71(1), 778–785.
52. Verdoni L, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020; 395(10239), 1771–1778.
53. Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. Journal of Clinical Investigation. 2020; 130(4), 1545–1548.
54. Maiztegui J, Alba J, Fernandez, NJ. Efficacy of immune plasma in treatmen of Argentine haemorrhagic fever and association between tratment and a late neurological syndrome. Lancet. 1979; 54(1), 1216–1217. 1216–1217.
55. Bloch EM, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. Journal of Clinical Investigation. 2020; 130(6), 2757–2765.
56. Adarsh Bhimraj A, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. www.idsociety.org/COVID19guidelines/treatment. 2020. Disponible en: www.idsociety.org/COVID19guidelines.
57. Duan K, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc. Natl. Acad. Sci. 202004168. 2020. doi:10.1073/pnas.2004168117
58. World Health Organization. Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases. 2020; 1–7.
59. Molina Arias, M. Lectura crítica en pequeñas dosis características de las pruebas diagnósticas. Pediatr. Aten. Primaria, 2013; 15(1), 169–173.
60. Amanat F, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 2020; 26(1), 1033-1036..
61. CDC. Interim Guidelines for COVID-19 Antibody Testing | CDC. (2020). Diponible en: https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html.